Next Article in Journal
Which Type of the Promising COVID-19 Vaccines Produces Minimal Adverse Effects? A Retrospective Cross-Sectional Study
Previous Article in Journal
Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates
Previous Article in Special Issue
A Placebo-Controlled, Double-Blind Randomized (Phase IIB) Trial of Oral Administration with HPV16 E7-Expressing Lactobacillus, GLBL101c, for the Treatment of Cervical Intraepithelial Neoplasia Grade 2 (CIN2)
vaccines-logo
Article Menu
Article

Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program

1
Department of Obstetrics and Gynecology, School of Medicine, Showa University, Tokyo 142-8666, Japan
2
Department of Gynecologic Oncology, Hyogo Cancer Center, Akashi 673-0021, Japan
3
Department of Gynecology and Obstetrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
4
Department of Gynecology, Cancer Institute Hospital, Tokyo 135-0063, Japan
5
Department of Gynecology, Saitama Cancer Center, Saitama 362-0806, Japan
6
Department of Gynecology, Kanagawa Cancer Center, Yokohama 241-8515, Japan
7
Gynecology Service, NHO Kyushu Cancer Center, Fukuoka 811-1395, Japan
8
Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama 791-0280, Japan
9
Department of Gynecology, Osaka International Cancer Institute, Osaka 541-8567, Japan
10
Department of Obstetrics and Gynecology, School of Medicine, Kurume University, Kurume 830-0011, Japan
11
Department of Obstetrics and Gynecology, Jichi Medical University, Shimotsuke 329-0498, Japan
12
Department of Obstetrics and Gynecology, Graduate School of Medicine, Tohoku University, Sendai 980-8575, Japan
13
Department of Obstetrics and Gynecology, Faculty of Medicine, Kindai University, Osaka 589-8511, Japan
14
Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama 350-1298, Japan
15
Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan
16
Department of Obstetrics and Gynecology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan
17
Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama 700-8558, Japan
18
Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
19
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan
20
Department of Gynecology, National Cancer Center Hospital, Tokyo 104-0045, Japan
21
Division of Gynecology, Shizuoka Cancer Center Hospital, Shizuoka 411-8777, Japan
22
Department of Obstetrics and Gynecology, Graduate School of Medicine, University of the Ryukyus, Nishihara 903-0215, Japan
23
Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
24
Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-8582, Japan
25
Division of Medical Engineering, Department of Information Science, Iwate Medical University, Yahaba 028-3694, Japan
26
Pathogen Genomics Center, National Institute of Infectious Diseases, Tokyo 208-0011, Japan
*
Author to whom correspondence should be addressed.
The MINT Study Group are indicated in the Acknowledgment section.
Academic Editor: Zheng Quan Toh
Vaccines 2022, 10(2), 188; https://doi.org/10.3390/vaccines10020188
Received: 26 November 2021 / Revised: 17 January 2022 / Accepted: 18 January 2022 / Published: 25 January 2022
Since the human papillomavirus (HPV) vaccination program for Japanese girls aged 12–16 years began in 2010, vaccination uptake has been low in women born before 1993 but high (approximately 70%) in those born during 1994–1999. We previously compared the prevalence of vaccine types HPV16 and HPV18 in cervical intraepithelial neoplasia grade 1–3 (CIN1–3) or adenocarcinoma in situ (AIS) between vaccinated and unvaccinated cohorts and found direct protection effects among vaccinated women in Japan. In this study, we focused on changes in HPV16/18 prevalence among “unvaccinated” cohorts with CIN/AIS. We analyzed HPV16/18 prevalence among 5051 unvaccinated women aged <40 years, newly diagnosed with CIN/AIS during 2012–2021 for time trends. Declining trends in HPV16/18 prevalence over 9 years were observed in CIN1 (36.0–10.0%, Ptrend = 0.03) and CIN2–3/AIS (62.5–36.4%, Ptrend = 0.07) among women aged <25 years. HPV16/18 prevalence in CIN1 and CIN2–3/AIS diagnosed at age 20–24 years was lower in 1994–1999 birth cohorts compared with 1988–1993 birth cohorts (4.5% vs. 25.7% for CIN1 and 40.0% vs. 58.1% for CIN2–3/AIS, both p = 0.04). Significant reduction in HPV16/18 prevalence among young unvaccinated women with CIN1 and CIN2–3/AIS suggests herd effects of HPV vaccination in Japan. View Full-Text
Keywords: adenocarcinoma in situ; cervical cancer; cervical intraepithelial neoplasia; human papillomavirus; vaccination adenocarcinoma in situ; cervical cancer; cervical intraepithelial neoplasia; human papillomavirus; vaccination
Show Figures

Figure 1

MDPI and ACS Style

Onuki, M.; Yamamoto, K.; Yahata, H.; Kanao, H.; Horie, K.; Konnai, K.; Nio, A.; Takehara, K.; Kamiura, S.; Tsuda, N.; Takei, Y.; Shigeta, S.; Nakai, H.; Yoshida, H.; Motohara, T.; Kato, T.; Nakamura, K.; Hamanishi, J.; Tasaka, N.; Ishikawa, M.; Kado, N.; Taira, Y.; Mori, M.; Iwata, T.; Takahashi, F.; Kukimoto, I.; Yoshikawa, H.; Yaegashi, N.; Matsumoto, K.; for the MINT Study Group. Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program. Vaccines 2022, 10, 188. https://doi.org/10.3390/vaccines10020188

AMA Style

Onuki M, Yamamoto K, Yahata H, Kanao H, Horie K, Konnai K, Nio A, Takehara K, Kamiura S, Tsuda N, Takei Y, Shigeta S, Nakai H, Yoshida H, Motohara T, Kato T, Nakamura K, Hamanishi J, Tasaka N, Ishikawa M, Kado N, Taira Y, Mori M, Iwata T, Takahashi F, Kukimoto I, Yoshikawa H, Yaegashi N, Matsumoto K, for the MINT Study Group. Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program. Vaccines. 2022; 10(2):188. https://doi.org/10.3390/vaccines10020188

Chicago/Turabian Style

Onuki, Mamiko, Kasumi Yamamoto, Hideaki Yahata, Hiroyuki Kanao, Koji Horie, Katsuyuki Konnai, Ai Nio, Kazuhiro Takehara, Shoji Kamiura, Naotake Tsuda, Yuji Takei, Shogo Shigeta, Hidekatsu Nakai, Hiroyuki Yoshida, Takeshi Motohara, Tatsuya Kato, Keiichiro Nakamura, Junzo Hamanishi, Nobutaka Tasaka, Mitsuya Ishikawa, Nobuhiro Kado, Yusuke Taira, Mayuyo Mori, Takashi Iwata, Fumiaki Takahashi, Iwao Kukimoto, Hiroyuki Yoshikawa, Nobuo Yaegashi, Koji Matsumoto, and for the MINT Study Group. 2022. "Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program" Vaccines 10, no. 2: 188. https://doi.org/10.3390/vaccines10020188

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop